Nick Abbott
Stock Analyst at Wells Fargo
(n/a)
# 3,298
Out of 4,479 analysts
7
Total ratings
n/a
Success rate
-45.36%
Average return
Main Sectors:
Top Industries:
6 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Assumes: Overweight | $45 → $9 | $8.40 | +7.14% | 1 | Oct 4, 2022 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $45 | $0.63 | +7,041.72% | 2 | Oct 4, 2022 | |
| ADAP Adaptimmune Therapeutics | Maintains: Equal-Weight | $7 → $1.5 | $1.05 | +42.86% | 1 | Oct 4, 2022 | |
| CALA Calithera Biosciences | Maintains: Equal-Weight | $60 → $40 | $0.01 | +319,900.00% | 1 | May 11, 2022 | |
| CLLS Cellectis | Downgrades: Equal-Weight | $16 | $1.89 | +746.56% | 1 | Jan 6, 2022 | |
| AFMD Affimed | Maintains: Overweight | $100 → $150 | $5.16 | +2,809.80% | 1 | Mar 24, 2021 |
Zymeworks
Oct 4, 2022
Assumes: Overweight
Price Target: $45 → $9
Current: $8.40
Upside: +7.14%
Alaunos Therapeutics
Oct 4, 2022
Assumes: Overweight
Price Target: $45
Current: $0.63
Upside: +7,041.72%
Adaptimmune Therapeutics
Oct 4, 2022
Maintains: Equal-Weight
Price Target: $7 → $1.5
Current: $1.05
Upside: +42.86%
Calithera Biosciences
May 11, 2022
Maintains: Equal-Weight
Price Target: $60 → $40
Current: $0.01
Upside: +319,900.00%
Cellectis
Jan 6, 2022
Downgrades: Equal-Weight
Price Target: $16
Current: $1.89
Upside: +746.56%
Affimed
Mar 24, 2021
Maintains: Overweight
Price Target: $100 → $150
Current: $5.16
Upside: +2,809.80%